Vaccines as monotherapy and in combination therapy for prostate cancer.
Prostate cancer is the second leading cause of cancer death among men in the United States. Standard-of-care chemotherapy for metastatic castration-resistant prostate cancer is associated with significant but modest survival benefit, indicating a need for alternative and/or additional approaches. The use of therapeutic cancer vaccines for the treatment of prostate cancer represents a novel targeted therapeutic approach. Whereas vaccine strategies are being developed for the treatment of various stages of prostate cancer, this article focuses on novel vaccine strategies for castration-resistant prostate cancer that have been translated into late-stage clinical studies.
Rotow
Julia
J
Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Gameiro
Sofia R
SR
Madan
Ravi A
RA
Gulley
James L
JL
Schlom
Jeffrey
J
Hodge
James W
JW
D003131:Combined Modality Therapy; D006801:Humans; D007167:Immunotherapy; D008297:Male; D017430:Prostate-Specific Antigen / Q000276:immunology; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000276:immunology* / Q000628:therapy; D014612:Vaccines / Q000276:immunology* / Q000627:therapeutic use*
D014612:Vaccines; D017430:Prostate-Specific Antigen